STOCK TITAN

Day One Biopharmaceuticals (NASDAQ: DAWN) filing shows 0% Atlas ownership

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Day One Biopharmaceuticals, Inc. Schedule 13G/A amendment shows a group of Atlas Venture entities collectively reporting zero beneficial ownership in the company’s common stock (CUSIP 23954D109). The filing lists multiple Atlas Venture partnerships and LLCs and is signed by Ommer Chohan on behalf of those entities.

Positive

  • None.

Negative

  • None.
Document date 03/31/2026 Cover date shown on the amendment
Signature date 05/14/2026 Date signatures by Ommer Chohan were executed
Beneficial ownership 0 shares Amount beneficially owned reported in Item 4(a)
Percent of class 0% Percent of class reported in Item 4(b)
CUSIP 23954D109 Identifier for Day One Biopharmaceuticals common stock
Schedule 13G/A regulatory
"Amendment No. 4 ) Day One Biopharmaceuticals, Inc."
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
Beneficial ownership financial
"Item 4. | Ownership (a) | Amount beneficially owned: 0"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Joint Filing Agreement regulatory
"Exhibit Information JOINT FILING AGREEMENT"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did the Schedule 13G/A filed for DAWN report?

The filing reports that Atlas Venture entities beneficially own 0 shares of Day One Biopharmaceuticals common stock, representing 0% of the class. It identifies multiple Atlas Venture partnerships and LLCs and provides a joint filing agreement signed by Ommer Chohan.

Which Atlas Venture entities are named in the DAWN filing?

Named reporting persons include Atlas Venture Fund XI, L.P., Atlas Venture Associates XI entities, Atlas Venture Opportunity Fund I and II entities, and affiliated LLCs. Each entity’s place of organization is listed as Delaware and the business address is in Cambridge, Massachusetts.

When were the signatures and document date recorded in the filing for DAWN?

The amendment shows a document date of 03/31/2026 on the cover and signature dates of 05/14/2026. Signatures are executed by Ommer Chohan on behalf of the various Atlas Venture reporting entities.

Does the Schedule 13G/A indicate any voting or dispositive power for Atlas Venture in DAWN?

No. The ownership table shows 0 for sole and shared voting power and sole and shared dispositive power, and lists beneficial ownership as 0 shares, representing 0% of the common stock class.





23954D109

(CUSIP Number)
03/31/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Atlas Venture Fund XI, L.P.
Signature:/s/ Ommer Chohan
Name/Title:By: Atlas Venture Associates XI, L.P., its GP, By: Atlas Venture Associates XI, LLC, its GP, By: Ommer Chohan, CFO
Date:05/14/2026
Atlas Venture Associates XI, L.P.
Signature:/s/ Ommer Chohan
Name/Title:By: Atlas Venture Associates XI, LLC, its GP, By: Ommer Chohan, CFO
Date:05/14/2026
Atlas Venture Associates XI, LLC
Signature:/s/ Ommer Chohan
Name/Title:Ommer Chohan, CFO
Date:05/14/2026
Atlas Venture Opportunity Fund I, L.P.
Signature:/s/ Ommer Chohan
Name/Title:By: Atlas Venture Associates Opportunity I, L.P., its GP, By: Atlas Venture Associates Opportunity I, LLC, its GP, By: Ommer Chohan, CFO
Date:05/14/2026
Atlas Venture Associates Opportunity I, L.P.
Signature:/s/ Ommer Chohan
Name/Title:By: Atlas Venture Associates Opportunity I, LLC, its GP, By: Ommer Chohan, CFO
Date:05/14/2026
Atlas Venture Associates Opportunity I, LLC
Signature:/s/ Ommer Chohan
Name/Title:Ommer Chohan, CFO
Date:05/14/2026
Atlas Venture Opportunity Fund II, L.P.
Signature:/s/ Ommer Chohan
Name/Title:By: Atlas Venture Associates Opportunity II, L.P., its GP, By: Atlas Venture Associates Opportunity II, LLC, its GP, By: Ommer Chohan, CFO
Date:05/14/2026
Atlas Venture Associates Opportunity II, L.P.
Signature:/s/ Ommer Chohan
Name/Title:By: Atlas Venture Associates Opportunity II, LLC, its GP, By: Ommer Chohan, CFO
Date:05/14/2026
Atlas Venture Associates Opportunity II, LLC
Signature:/s/ Ommer Chohan
Name/Title:Ommer Chohan, CFO
Date:05/14/2026
Exhibit Information

JOINT FILING AGREEMENT